Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Piroxicam and carboplatin in canine oral non-tonsillar squamous cell carcinoma
Squamous cell carcinomas of the oral mucosa are known to be very aggressive and often very frustrating in their therapy. Does this combination of carboplatin and piroxicam coming from human medicine offer better therapeutic results than the current therapies? At least the preliminary results seems to be promising!

Results of the treatment with a combination of carboplatin and piroxicam in seven dogs with advanced non-tonsillar oral squamous cell carcinoma (SCC) were retrospectively analysed.

This multi-agent protocol was well tolerated by all dogs and resulted in a complete regression of the tumour without additional surgery in four of seven patients.
Additional surgery was necessary to remove a metastatic lymph node in one dog and residual tumour in a second dog, which achieved a partial response following medical therapy.

Median follow-up for all the dogs was 534 days, while the time-to-recurrence, time-to-progression and overall survival for this group of patients have not yet been reached.

Our study, although limited in number of animals, suggests that this multiagent approach is a useful treatment option for oral non-tonsillar SCC in dogs and warrants wider application.



Source: de Vos, J. P., Burm, A. G. D., Focker, A. P., Boschloo, H., Karsijns, M. & van der Waal, I. (2005): Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma. In: Veterinary and Comparative Oncology 3 (1), 16-24.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Surgical outcome of cats treated for aqueous humor misdirection syndrome
Feline aqueous humor misdirection syndrome is occasionally seen in cats and can be difficult to treat. This recently online published case series evaluates the clinical outcome of cats treated surgically for aqueous humor misdirection syndrome.

  • Treatment of limbal melanoma with surgical debulking plus diode laser
  • Novel technique to place feeding tubes in small animalsmembers
  • Epidemiology and clinical presentation of canine cataracts in France
  • Use of a Surgical Safety Checklistmembers
  • NGAL in dogs with chronic kidney diseasemembers
  • Long-term Outcome of Irish Wolfhound Dogs with different heart medicationsmembers
  • Simple technique for autotransfusion in dogsmembers
  • General anesthesia with an injectable 8% v/v sevoflurane lipid emulsion in dogsmembers
  • Carboplatin sustained-release delivery system in dogs with cancermembers
  • Wound bio-burden and prevalence of multi-drug resistant bacteria in open woundsmembers
  • Concurrent perioperative use of marbofloxacin and cimicoxib or carprofenmembers
  • Topical hyaluronic acid and the corneal wound healing members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved